Sayre Therapeutics offers clinicians a convenient and effective oral formulation of Tegafur ( pro-drug of 5-FU) with Uracil for the management of metastatic colorectal cancer.
- Indication: TEGAFUR 100mg + URACIL 224mg capsules is indicated for the first line treatment of metastatic colorectal cancer with calcium folinate.
- Formulation: TEGAFUR 100mg + URACIL 224mg capsules are supplied as 1× 10’s Blister pack.
- Utegcil® is:
- Has comparable clinical efficacy to bolus 5-FU/LV in patients with metastatic colorectal cancer.
- When administered with Leucovorin, provides better safety profile compared with 5-FU/LV.
- More than 80% of patients preferred oral Tegafur/Uracil to I.V. bolus 5-FU.
-Convenience coupled with uncompromised clinical outcome